Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer
Ru M. Wen(Stanford Medicine), James D. Brooks(Cancer Research Institute), Rosalie Nolley(Stanford University), Xiangyue Zhang(Stanford University), Sharon J. Pitteri, Fernando Jose Garcia Marques(Canary Institute of Cancer Research), Hongjuan Zhao(Stanford University), G. Edward Marti(National Institute of Standards and Technology), Edgar G. Engleman(Stanford University), Aram Lyu(Fred Hutch Cancer Center), Zenghua Fan(University of California, San Francisco), Lawrence Fong(University of California, San Francisco), Sarah M. Totten(University of California, Davis), Carolyn R. Bertozzi(Stanford University), Jessica C. Stark(Stanford University), Abel Bermudez(Canary Institute of Cancer Research), Nicholas M. Riley(Stanford University)
Cited by 41
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
|Annual Review of Pathology Mechanisms of Disease|2020|2.2k
Symbol Nomenclature for Graphical Representations of Glycans
|Glycobiology|2015|1.1k
How many human proteoforms are there?
|Nature Chemical Biology|2018|942
Systematic evaluation of an atomic clock at 2 × 10−18 total uncertainty
|Nature Communications|2015|754